Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial; In an interim analysis, CheckMate -274 met primary endpoints

Press/Media

Period24 Sep 2020

Media coverage

20

Media coverage